Retrospective audit of a convenience cohort of individuals on HIV pre-exposure prophylaxis in Alberta, Canada.

Autor:	Candler E; STI Services, Alberta Health Services, Edmonton, Alberta, Canada., Naeem Khan M; Health Protection Communicable Disease Control, Population, Public and Indigenous Health, Alberta Health Services, Edmonton, Alberta, Canada., Gratrix J; STI Services, Alberta Health Services, Edmonton, Alberta, Canada., Plitt S; Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada., Stadnyk M; STI Services, Alberta Health Services, Edmonton, Alberta, Canada., Smyczek P; STI Services, Alberta Health Services, Edmonton, Alberta, Canada., Anderson N; Sexual and Reproductive Health Clinics, Calgary, Alberta, Canada., Carter J; Sexual and Reproductive Health Clinics, Calgary, Alberta, Canada., Sayers S; DxMedical Clinics, Edmonton, Alberta, Canada., Smith D; Red Deer Sexual Health Clinic, Red Deer, Alberta, Canada., Ugarte-Torres A; Department of Medicine, Division of Infectious Diseases, University of Calgary, Calgary, Alberta, Canada., Shukalek C; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada., Singh AE; University of Alberta, Edmonton, Alberta, Canada.
Jazyk:	angličtina
Zdroj:	Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada [J Assoc Med Microbiol Infect Dis Can] 2022 Nov 29; Vol. 7 (4), pp. 350-363. Date of Electronic Publication: 2022 Nov 29 (Print Publication: 2022).
DOI:	10.3138/jammi-2022-0016
Abstrakt:	Background: We undertook an audit of a province-wide HIV pre-exposure prophylaxis (PrEP) program in Alberta (Canada). Methods: A retrospective record review of individuals accessing PrEP in Alberta included demographics, PrEP indication(s), and reported non-prescription drug and alcohol use from March 2016 to June 2019. Hepatitis A, B, C, HIV and syphilis serology, serum creatinine, and nucleic acid amplification tests testing for chlamydia and gonorrhea were collected. Descriptive statistics, incidence, and prevalence were calculated. Results: A total of 511 participants were seen at STI, sexual, and reproductive health clinics and private family practitioner (FP) offices; 98.4% (503) were men, median age was 34 years (IQR 28-43 years), and 89.8% (459) were gay or bisexual men who have sex with men. Non-prescription drug use was reported by 39.3% (201) and alcohol use by 55.4% (283). 94.3% (482) reported condomless anal sex in the past 6 months. Testing rates were high (>95%) for all tests except for chlamydia and gonorrhea at the first follow-up visit 89.6%; (3-4 months). There was one HIV seroconversion. The incidence of new bacterial STIs was high: chlamydia 17 cases per 100 person-years (95% CI 13.5% to 21.4%), gonorrhea 11.14 cases per 100 person-years (95% CI 8.3% to 15.0%), and syphilis 1.94 cases per 100 person-years (95% CI 0.73% to 5.12%). Conclusions: Following implementation of a provincial program for PrEP in Alberta, PrEP initiation and continuation was feasible in a range of settings and by both specialists and FPs. Competing Interests: AE Singh received consulting fees from Gilead; C Shukalek received grants or contracts from CIHR and the Royal College of Physicians and Surgeons, consulting fees and payment for speaking engagements from Gilead and Merck Canada, stock options from Purpose Med, and is a board member of The SHARP Foundation. The other authors have nothing to disclose. (Copyright © 2022, Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu